Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.
Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R. Hoffmann VS, et al. Among authors: turkina ag. Leukemia. 2015 Jun;29(6):1336-43. doi: 10.1038/leu.2015.73. Epub 2015 Mar 18. Leukemia. 2015. PMID: 25783795
Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhiac-Llacer PE, Zheng M, Szczudlo T, Turkina A. Nicolini FE, et al. Leuk Lymphoma. 2012 May;53(5):907-14. doi: 10.3109/10428194.2011.627480. Epub 2011 Dec 5. Leuk Lymphoma. 2012. PMID: 22023530 Clinical Trial.
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R. Hoffmann VS, et al. Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29. Leukemia. 2017. PMID: 27568522
[Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy].
Turkina AG, Chelysheva EY, Shuvaev VA, Gusarova GA, Bykova AV, Shukhov OA, Petrova AN, Vakhrusheva MV, Goryacheva SR, Kolosova LY, Krasikova PS, Fominykh MS, Martynkevich IS, Abdullaev AO, Sudarikov AB, Savchenko VG. Turkina AG, et al. Ter Arkh. 2017;89(12):86-96. doi: 10.17116/terarkh2017891286-96. Ter Arkh. 2017. PMID: 29411766 Russian.
Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.
Smirnikhina SA, Chelysheva EY, Lavrov AV, Kochergin-Nikitsky KS, Mozgovoy IV, Adilgereeva EP, Shukhov OA, Petrova AN, Bykova AV, Abdullaev AO, Turkina AG, Kutsev SI. Smirnikhina SA, et al. Among authors: turkina ag. Leuk Lymphoma. 2018 Oct;59(10):2512-2515. doi: 10.1080/10428194.2018.1434880. Epub 2018 Feb 9. Leuk Lymphoma. 2018. PMID: 29424604 No abstract available.
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Mahon FX, et al. Among authors: turkina ag. Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20. Ann Intern Med. 2018. PMID: 29459949 Clinical Trial.
91 results